Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02850536 · ClinicalTrials.gov registry record · Phase 1
CAR-T Hepatic Artery Infusions or Pancreatic Venous Infusions for CEA-Expressing Liver Metastases or Pancreas Cancer
A Phase 1 study of Liver Metastases, sponsored by Roger Williams Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
- 2
- Study locations
NCT02850536: Completed Phase 1 study of Liver Metastases, sponsored by Roger Williams Medical Center.
NCT02850536 is a Phase 1 study of Liver Metastases that has completed, run by Roger Williams Medical Center. The registered enrollment target is 5 participants, below the 68-participant average among 27 other Liver Metastases trials with a reported enrollment target (93% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02850536, a Phase 1 study of Liver Metastases, has completed, sponsored by Roger Williams Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is an open label, fixed dose, phase Ib trial of anti-CEA CAR-T cell infusions delivered via the hepatic artery or splenic vein using the Surefire Infusion System (SIS) for patients with CEA-expressing liver metastases or pancreas cancer.
Primary Outcome
To determine the safety and regimen limiting toxicity (RLT) of anti-CEA CAR-T hepatic artery infusions (HAI) via the Surefire Infusion System (SIS) for CEA-expressing liver metastases
Conditions Studied
Interventions
- BIOLOGICAL anti-CEA CAR-T cells
Study Locations (2)
Colorado
- University of Colorado Hospital - Aurora
Rhode Island
- Roger Williams Medical Center - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2017-02-01 |
| Est. Completion | 2021-09-17 |
| Phase | Phase 1 |
What the finished NCT02850536 record still lists
NCT02850536 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 68-participant average among 27 other Liver Metastases trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Liver Metastases appearing as the primary indexed condition, and to 1 intervention - of which anti-CEA CAR-T cells is the first listed.
NCT02850536 reports a single indexed study location in Colorado, Rhode Island.
Frequently Asked Questions
What is clinical trial NCT02850536 about?
NCT02850536 is a clinical study titled "CAR-T Hepatic Artery Infusions or Pancreatic Venous Infusions for CEA-Expressing Liver Metastases or Pancreas Cancer". This is an open label, fixed dose, phase Ib trial of anti-CEA CAR-T cell infusions delivered via the hepatic artery or splenic vein using the Surefire Infusion System (SIS) for patients with CEA-expressing liver metastases or pancreas cancer.
What is the current status of trial NCT02850536?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2017-02-01. Estimated completion is 2021-09-17.
What conditions does trial NCT02850536 study?
This clinical trial studies the following conditions: Liver Metastases.
What interventions are being tested in trial NCT02850536?
The interventions under investigation include: anti-CEA CAR-T cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT02850536?
This trial is sponsored by Roger Williams Medical Center, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02850536 being conducted?
This trial has 2 study locations across Colorado, Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liver Metastases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02850536's enrollment target sits among peer trials
5 27th of 27 higher than 1 of 27 other Liver Metastases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Liver Metastases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis
RECRUITING · Phase 1
-
Liver SBRT in Combination With Immune Checkpoint Inhibition in Patients With Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases
COMPLETED · Phase 1
-
Hepatic Arterial Infusion of Floxuridine, Gemcitabine Hydrochloride, and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer Previously Treated With Surgery
COMPLETED · Phase 1
-
CAR-T Hepatic Artery Infusions and Sir-Spheres for Liver Metastases
COMPLETED · Phase 1
-
Promoting Immunotherapy Efficacy With Low-Dose Liver RT
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI